between April 2014 and March 2018 were enrolled. Differences on patients’ background and clinical parameters between MCAP and CAP caused by S. pneumoniae (SCAP) were compared with elucidate the clinical characteristics of MCAP. Patients with bed-ridden status, residents in nursing home, more than two microorganisms were detected from sputum, were excluded.

Results. During the study period, 114 MCAP and 107 SCAP were identified. In two groups, general status was mild (score ≤2 was 65.7% vs. 64.4%) according to Japanese pneumonia severity scoring system (A-DROP), and the qSOFA score was also relatively low (score ≤2 was 95.6% vs. 91.5%). Although there was no difference in the ratio of sex in these groups, the age was significantly higher in MCAP cohort (the mean age; 77 vs. 68 years old, P < 0.01). Compared with SCAP, MCAP had significantly higher pulmonary underlying diseases such as bronchiectasis (P < 0.01), asthma (P < 0.05), interstitial pneumonia (P < 0.05), and lung cancer (P < 0.05), home oxygen therapy (P < 0.01), and systemic disease (P < 0.05). Diagnostic concordance rate between sputum smear on Gram-stain and bacterial cultivation was lower in MCAP patients (78% vs. 87.8%; P = 0.05). In radiological findings, broncho pneumonia pattern was predominant in MCAP group than PCAP group (95.6% vs. 62.6%; P < 0.01). On the other hand, developing a chill and respiratory symptoms with fever were used commonly in PCAP patients (P < 0.01). There was no statistical significant difference on length of treatment and hospital stay in two groups (P = 0.66 and 0.55, respectively). All patients in both groups recovered.

Conclusion. In the present study, the characteristics of MCAP were as follows; (i) mainly occurred in elderly patients under pulmonary and systemic diseases, (ii) presented with relatively mild symptoms, (iii) bronchopneumonia pattern was predominant, and (iv) benign prognosis.

Disclosures. All authors: No reported disclosures.

1451. Predictive Values of Methylcillin-Resistant Staphylococcus aureus (MRSA) Nasal Swab PCR Assay for MRSA Pneumonia
Man Ting Chou, PharmD; Romic Eskandarian, PharmD; Hemi Jung, PharmD; Ross Pineda, PharmD; Candidate 2019; Su Lee, PharmD and Keitaro Kawaguchi, PharmD; Adventist Health Glendale, Glendale, California, 4School of Pharmacy, West Coast University, Los Angeles, California

Session: 147. Respiratory Infections: CAP
Friday, October 5, 2018: 12:30 PM

Background. The Center for Disease Control (CDC) reports that methicillin-resistant Staphylococcus aureus (MRSA) has been linked to over 80,000 severe infections and 11,000 deaths per year. Due to this concern, patients are commonly and overly treated with antibiotics. Methicillin-resistant Staphylococcus aureus (MRSA) is often found in the nares, and MRSA nasal carriers are used commonly in organ transplantation settings. This PCR method may take days to result. Recent emerging literature suggests that the use of MRSA nasal swab PCR assay as a predictive diagnostic tool for MRSA pneumonia can shorten the duration of empiric therapy. The primary objective of this study was to assess both the positive and negative predicative values of the MRSA nasal swab for MRSA pneumonia.

Methods. We conducted a single-centered, retrospective chart review of all patients admitted from February 2017 to 2018 with a confirmed diagnosis of pneumonia and had not returned to the hospital within 48 hours of the screening were included in this study. Patients who failed to meet these criteria, they were excluded from the study. This study has been exempt from the Institutional Review Board (IRB).

Results. One hundred seventy-four patients met the inclusion criteria, 30 with positive MRSA nares and 144 with negative MRSA nares. No statistical differences were found between baseline characteristics between the two groups. The positive predictive value of the MRSA nasal swab for MRSA pneumonia was 0.3 and its negative predictive value was 0.97. The sensitivity was 64% and the specificity was 87%.

Table 1. Predictive Values of MRSA Nasal Swab for MRSA Pneumonia

| Respiratory Culture | Respiratory Culture | Predictive Value (N = 160) |
|---------------------|---------------------|----------------------------|
| MRSA Nares (+) (N = 30) | 9 | 21 | 0.3 |
| MRSA Nares (+) (N = 144) | 5 | 129 | 0.97 |

Conclusion. MRSA nasal swab has a high negative predictive value to rule out MRSA pneumonia and reduces time to discontinuance of empiric MRSA-targeted antimicrobial agents. The positive predictive value was low and should not be used as a sole factor to initiate antimicrobial therapy.

Disclosures. All authors: No reported disclosures.

1452. Non-invasive Pneumococcal Pneumonia in Adults in Portugal: Continued Decline of PCV13 Serotypes (2015–2017)
Catarina Silva-Costa, PhD; Elisia Lopes, MSc; Mario Ramirez, PhD; Jose Malo-Cristino, MD, PhD and Portuguese Group for the Study of Streptococcal Infections; Instituto De Microbiologia, Instituto De Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

Session: 147. Respiratory Infections: CAP
Friday, October 5, 2018: 12:30 PM

Background. In 2015, PCV13 was introduced in the National Immunization Plan in Portugal for children, although it was not significantly used in adults. However, changes in the pneumococcal population causing non-invasive pneumococcal pneumonia (NIPP) in adults (218 years) can occur due to herd effects. To evaluate this, we monitored the serotypes and antimicrobial resistance of adult NIPP isolates in 2015-2017.

Methods. A total of 1,142 isolates were recovered, serotyped by Quellung and tested for susceptibility to antimicrobials by disk diffusion or Etest.

Results. Among the 1,142 isolates, 52 different serotypes were found and 59 isolates were not typeable (5%). The most common were serotypes 3 (13%), 19F (8%), 19E, 9N and 23A (5% each), 23B, 16F and 6C (4% each). There were strong variations in the proportion of some serotypes, suggesting that factors other than vaccine pressure could also impact on serotype prevalence. Although a considerable number of isolates were still serotyped the additional serotypes included in PCV13 (addPCV13 = 200), the overall proportion of addPCV13 serotypes remained relatively stable in this time period. However, when comparing with the previous period (2012-2014), there was a significant decrease in the proportion of addPCV13 serotypes, from 22 to 17.7% (P < 0.01). From 2014 to 2015, 11 patients with sputum smear on Gram-stain and bacterial cultivation were negative, which were found to be positive, in the addPCV13 serotypes exclusively.

Conclusion. After the introduction of PCV13 in the National Immunization Plan for children, a significant decrease in the proportion of PCV13 serotypes was noted in the adult population, although a considerable fraction of disease is still caused by vaccine serotypes. Moreover, nonvaccine serotypes are becoming important causes of NIPP, emphasizing the importance of continued surveillance studies.

Disclosures. M. Ramirez, Pfizer: Speaker's Bureau, Speaker honorarium; Glassmething.com: Consultant, Consulting fee; Merck Sharp and Dohme: Consultant, Consulting fee. J. Melo-Cristino, Pfizer: Grant Investigator and Speaker's Bureau, Research grant and Speaker honorarium; Merck Sharp and Dohme: Speaker's Bureau, Speaker honorarium.

1453. Ninety-One Day Quality of Life Post-Pneumonia Diagnosis in Adult Patients in Japan
Henry Glick, PhD; Taiga Miyazaki, MD, PhD; Katsuki Hirano, MD; Jose Suaya, MD, PhD; Elisa Gonzalez, MS; Bradford D. Gessner, MD; Raul E. Isturiz, MD; Adrian G. Arguedas, MD; Shigeru Kohno, MD; General Internal Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 3Second Department of Internal Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Pneumococcal Vaccines, WW Medicines Development & Scientific Affairs, Pfizer Inc, New York, New York, 5Pfizer, Inc., Collegeville, Pennsylvania

Session: 147. Respiratory Infections: CAP
Friday, October 5, 2018: 12:30 PM

Background. Pneumonia is a serious illness with potentially long-lasting but poorly-characterized impact on quality of life. The Japanese Goto Epidemiology Study is a prospective, active, population-based surveillance study of patients with community-onset pneumonia (COMP), that includes assessment of Quality Adjusted Life Years (QALYs).

Methods. Patients with X-ray/CT scan confirmed COP enrolled in the Goto cohort study. They were consented to participate in QALY assessment responded to Japanese versions of EuroQol-5D-5L (EQ-5D-5L) health state classification (primary), EQ-5D visual analog scale, and SF-6D (secondary) instruments. This interim analysis reports 91-day QALYs based on Day 1 (diagnosis), 8, 16, 31, and 91 EQ-5D-5L responses of patients enrolled between June 1, 2017 and February 28, 2018. In the interim, we developed hypothetical QALYs had the patients not developed pneumonia (control) using the EQ-5D-5L scores from Day -30 (via recall) carried forward and adjusted by the natural decline in scores and death with age. QALYs were calculated as the area under the survival weighted pneumonia and control EQ-5D-5L QALY score curves.

Results. The 234 patients were 55% male, 88% aged 264 years, 45% nursing home residents, and 65% initially hospitalized (55% initially outpatient) for COP. Compliance for interviews among survivors was 100%. EQ-5D-5L scores were 0.732 at Day –30, decreased to 0.590 at diagnosis, and rose to 0.675 by Day 91. The average scores at all time points remained below Day –30 (all P values <0.01). Compared with hypothetical controls, development of pneumonia on average resulted in a loss of 0.0292 QALYs (P < 0.001) during the first 91 days of follow-up.

Conclusion. Among residents of Goto Island, Japan, significant QALY losses were observed in association with a diagnosis of pneumonia and had not returned to baseline by 3 months after diagnosis. Scores and cumulative QALY losses during the first 3 months after pneumonia diagnosis were comparable to those experienced by US adults with chronic heart failure during a 3-month period.

Disclosures. H. Glick, K. Hirano, Pfizer Inc.: Consultant, Research support. T. Miyazaki, Pfizer Inc.: Collaborator, Research support and Speaker honorarium. J. Suaya, M. Ramirez, B. D. Gessner, A. G. Arguedas, Pfizer Inc.: Employee and Shareholder. Salary. R. E. Isturiz, Pfizer, Inc: Employee and Shareholder, Salary and Stock & Stock Options. S. Kohno, Pfizer Inc.: Consultant, Research support and Speaker honorarium.